Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
2026年 3月 17日
Read MoreZai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
2026年 2月 26日
Read MoreZai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
2026年 2月 10日
Read MoreZai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
2026年 1月 13日
Read MoreZai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
2026年 1月 6日
Read More